Prognostic significance of intracranial dissemination of glioblastoma multiforme in adults

被引:105
|
作者
Parsa, AT [1 ]
Wachhorst, S [1 ]
Lamborn, KR [1 ]
Prados, MD [1 ]
McDermott, MW [1 ]
Berger, MS [1 ]
Chang, SM [1 ]
机构
[1] Univ Calif San Francisco, Sch Med, Dept Neurol Surg, San Francisco, CA 94143 USA
关键词
tumor dissemination; multifocal lesion; glioblastoma multiforme; glioma; survival;
D O I
10.3171/jns.2005.102.4.0622
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Object. The clinical outcome and treatment of adult patients with disseminated intracranial glioblastoma multiforme (GBM) is unclear. The objective in the present study was to assess the prognostic significance of disseminated intracranial GBM in adults at presentation and at the time of tumor progression. Methods. Clinical data from 1491 patients older than 17 years and harboring a GBM that had been diagnosed between 1988 and 1998 at the University of California at San Francisco neurooncology clinic were retrospectively reviewed. Dissemination of the GBM (126 patients) was determined based on Gd-enhanced magnetic resonance images. Classification of dissemination was as follows: Type I, single lesion with subependymal or subarachnoid spread; Type II, multifocal lesions without subependymal or subarachnoid spread; and Type III, multifocal lesions with subependymal or subarachnoid spread. Subgroups of patients were compared using Kaplan-Meier curves that depicted survival probability. The median postprogression survival (PPS), defined according to neuroimaging demonstrated dissemination, was 37 weeks for Type I (23 patients), 25 weeks for Type II (50 patients), and 10 weeks for Type III spread (19 patients). Patients with dissemination at first tumor progression (52 patients) overall had a shorter PPS than those in a control group with local progression, after adjusting for age, Karnofsky Performance Scale score, and time from tumor diagnosis to its progression (311 patients). When analyzed according to tumor dissemination type, PPS was significantly shorter in patients with Type II (33 patients, p < 0.01) and Type III spread (11 patients, p < 0.01) but not in those with Type I spread (eight patients, p = 0.18). Conclusions. Apparently, the presence of intracranial tumor dissemination on initial diagnosis does not in itself preclude aggressive treatment if a patient is otherwise well. A single focus of GBM that later demonstrates Type I dissemination on progression does not have a worse prognosis than a lesion that exhibits only local recurrence.
引用
收藏
页码:622 / 628
页数:7
相关论文
共 50 条
  • [21] Prognostic significance of galectin-1 expression in patients with glioblastoma multiforme following radiotherapy
    Huang, Eng-Yen
    Chou, Shang-Yu
    [J]. CANCER RESEARCH, 2017, 77
  • [23] Integrative Analyses and Verification of the Expression and Prognostic Significance for RCN1 in Glioblastoma Multiforme
    Lu, Weicheng
    Chen, Hong
    Liang, Bo
    Ou, Chaopeng
    Zhang, Mingwei
    Yue, Qiuyuan
    Xie, Jingdun
    [J]. FRONTIERS IN MOLECULAR BIOSCIENCES, 2021, 8
  • [24] Prognostic factors for glioblastoma multiforme - Development of a prognostic index
    Gundersen, S
    Lote, K
    Hannisdal, E
    [J]. ACTA ONCOLOGICA, 1996, 35 : 123 - 127
  • [25] OUT COME OF GLIOBLASTOMA MULTIFORME IN ADULTS
    Masood, U.
    Haider, I.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2011, 99 : S248 - S248
  • [26] IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme
    Kalkan, Rasime
    Atli, Emine Ikbal
    Ozdemir, Muhsin
    Ciftci, Evrim
    Aydin, Hasan Emre
    Artan, Sevilhan
    Arslantas, Ali
    [J]. GENE, 2015, 554 (01) : 81 - 86
  • [27] Prognostic relevance of MAPK expression in glioblastoma multiforme
    Mawrin, C
    Diete, S
    Treuheit, T
    Kropf, S
    Vorwerk, CK
    Boltze, C
    Kirches, E
    Firsching, R
    Dietzmann, K
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2003, 23 (03) : 641 - 648
  • [28] The significance of MGMT methylation in Glioblastoma Multiforme prognosis
    Rao, Aaida Mumtaz
    Quddusi, Ayesha
    Shamim, Muhammad Shahzad
    [J]. JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2018, 68 (07) : 1137 - 1139
  • [29] CLINICAL SIGNIFICANCE OF KALLIKREIN 6 IN GLIOBLASTOMA MULTIFORME
    Drucker, Kristen L.
    [J]. NEURO-ONCOLOGY, 2012, 14 : 16 - 16
  • [30] Epidermal growth factor receptor amplification does not have prognostic significance in patients with glioblastoma multiforme
    Quan, AL
    Barnett, GH
    Lee, SY
    Vogelbaum, MA
    Toms, SA
    Staugaitis, SM
    Prayson, RA
    Peereboom, DM
    Stevens, GHJ
    Cohen, BH
    Suh, JH
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (03): : 695 - 703